RxDoctor Payments Data

Anita Mannancheril, MD

Family Medicine · Bridgewater, NJNPI 1184962771

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 55 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$325
  • AbbVie$241
  • Pfizer$222
  • Merck$59
  • Bayer$53
  • Takeda Pharmaceuticals U.S.A., Inc.$45
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$1,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk14$325
AbbVie(2 entities)9$241
Pfizer14$222
Merck4$59
Bayer3$53
Takeda Pharmaceuticals U.S.A., Inc.3$45
Lilly USA, LLC3$43
Bausch Health US, LLC2$28
Corcept Therapeutics1$22
Aero US Inc1$22
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$78,077
Medicare patients
176
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$24,282
MounjaroTirzepatide19$22,916
EliquisApixaban11$7,846
SynthroidLevothyroxine Sodium24$1,702
Atorvastatin Calcium116$971
Levothyroxine Sodium98$954
Rosuvastatin Calcium74$859
Nifedipine ErNifedipine12$657
Losartan Potassium39$534
Levetiracetam12$484
Lisinopril60$467
Sertraline Hcl39$458
Albuterol Sulfate HfaAlbuterol Sulfate22$417
Metoprolol Succinate30$404
Gabapentin17$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$325$24,28215 claims
Lilly USA, LLCMounjaro$43$22,91619 claims
PfizerEliquis$222$7,84611 claims
AbbVieSynthroid$241$1,70224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →